Opinion|Videos|January 3, 2025
Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches
Panelists discuss how clinicians should implement regular cardiovascular monitoring and dose modifications for ponatinib-associated toxicities while being vigilant for asciminib’s key adverse events, including thrombocytopenia, pancreatic dysfunction, and hypertension, with appropriate dose adjustments and supportive care as needed.
Advertisement
Video content above is prompted by the following:
- What is your approach to monitoring and managing cardiovascular toxicities associated with ponatinib?
- What adverse events should clinicians be aware of with asciminib, and what is your approach to monitoring and managing these?
Advertisement
Related to this article
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
2
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
3
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
4
Dr Bianchi on the Mechanism of Anselamimab in AL Amyloidosis
5